Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|October 24, 2008
Model curriculum for academic child and adolescent psychiatry trainingDorothy Stubbe, Andrés Martin, Michael Bloch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled TrialRonald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, et al.
AEM Education and Training|July 28, 2018
Identifying the Emergency Medicine Personality: A Multisite Exploratory Pilot StudyJaime Jordan, Judith A Linden, Martine C Maculatis, et al.
Plos One|February 6, 2014
Inhibition of renin angiotensin axis may be associated with reduced risk of developing venous thromboembolism in patients with atherosclerotic diseaseYoung Kwang Chae, Danai Khemasuwan, Anastasios Dimou, et al.
Rheumatology (Oxford, England)|December 14, 2020
Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPYVibeke Strand, Namita Tundia, Alvin Wells, et al.
Rheumatology and Therapy|May 18, 2023
Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension StudyAlan Kivitz, Alvin F Wells, Juan I Vargas, et al.
Modern Rheumatology|November 9, 2020
Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY studyTsutomu Takeuchi, Maureen Rischmueller, Ricardo Blanco, et al.
Rheumatology (Oxford, England)|December 13, 2021
Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 programCharles G Peterfy, Vibeke Strand, Alan Friedman, et al.
Pageof 8